Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Wellbeing Digital Sciences Inc KONEF

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company. The Company is focused on the development and implementation of clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. It operates through three segments: Wellbeing & IRP; KGK Science and Mindscape. It operates medical clinics across North America to help its patients access plant-based medicines, psychedelics, and other forms of mental health care, all of which have the potential to heal them of their physical and/or emotional pain. Its subsidiaries include Mindscape Ketamine & Infusions Therapy LLC, KGK Science Inc. and Integrated Rehab and Performance Ltd. It is supported by a network of North American clinics that provide therapies and other types of treatment to patients, as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.


GREY:KONEF - Post by User

Post by StockHawk1on Dec 21, 2021 5:45pm
231 Views
Post# 34252482

Big internal update for $MEDI

Big internal update for $MEDI

Ketamine One ($MEDI.N $KONEF) publicized an internal update yesterday, announcing their 2021 Annual General and Special Meeting results.


The ketamine-focused mental health treatment company had 11 shareholders represented in person or by proxy at the meeting which was held in mid-December.


Together the 11 shareholders held +18.8K (or 15.69%) of the Company’s total issued and outstanding common shares.


Some important issues voted on at the meeting:

- Setting the number of directors to 4 

- Overwhelmingly the voters voted to elect all the nominees for Director positions: Henning, Raey, Inglefield, and Purdy.

- Macias Gini & O’Connell were reappointed as Auditors 

- The voters authorized and approved of the restricted share unit plan 


Full update here: https://ca.finance.yahoo.com/news/ketamine-one-announces-2021-agsm-161100449.html


$MEDI @ $0.38 (slightly down), MC $39.273M
<< Previous
Bullboard Posts
Next >>